Oxis Turbuhaler Inhaler / Dry Powder
Formoterol Fumarate
9mcg/Dose
ASTRAZENECA AB
| Pack size | 60 Dose Inhaler |
|---|---|
| Dispensing mode | POM |
| Source | SWEDEN |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 118.50 AED |
Available as:
Indications
Oxis Turbuhaler Inhaler / Dry Powder is used for:
Asthma, Chronic bronchitis, Emphysema, COPD
Adult Dose
Inhalation
Prophylaxis of exercise-induced asthma
Adult: 12 mcg at least 15 min prior to exercise. Additional doses should not be taken w/in 12 hr.
Asthma
Adult: As inhalation cap: 12 mcg bid via inhaler device, may be increased up to 24 mcg bid as necessary for severe cases.
Chronic obstructive pulmonary disease
Adult: As inhalation cap: 12 mcg bid via inhaler device.
As metered-dose dry powd inhaler: 12 mcg 1-2 times daily.
Additional doses may be given as required. Max: 48 mcg/day (24 mcg/dose).
Child Dose
Inhalation
Prophylaxis of exercise-induced asthma
Child: >5 yr 12 mcg at least 15 min prior to exercise. Additional doses should not be taken w/in 12 hr.
Asthma
Child: As inhalational cap: >5 yr 12 mcg bid via inhaler device.
As metered-dose dry powd inhaler: >6 yr 6-12 mcg 1-2 times daily.
Renal Dose
Administration
Contra Indications
Hypersensitivity.
Precautions
Thyrotoxicosis; severe CV disorders e.g. ischaemic heart disease, tachyarrhythmias or severe heart burn; prolonged QT-interval. DM; pregnancy; lactation; children <5 yr; do not initiate or increase the dose during an exacerbation. May produce paradoxical bronchospasm.
Lactation: not known if excreted in breast milk, use caution
Pregnancy-Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk, use caution
Interactions
Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a possible hypokalaemic effect of beta-agonists. Increased susceptibility to cardiac arrhythmias in patients treated with digitalis. Concomitant use with quinidine, disopyramide, procainamide, phenothiazines, antihistamines, MAOI or TCAs can prolong the QT-interval and increase the risk of ventricular arrhythmias. L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards beta2-sympathomimetics. beta-adrenergic blockers can inhibit the effect of formoterol. Increased risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.
Adverse Effects
Side effects of Formoterol Fumarate :
>10%
Viral infection (17.2%)
1-10%
Bronchitis (4.6%), Chest infection (2.7%), Dyspnea (2.1%), Chest pain (1.9%), Tremor (1.9%), Dizziness (1.6%)
Frequency Not Defined
Angina, Arrhythmias, Hypo/hypertension, Tachycardia, Hypokalemia, Hyperglycemia, Metabolic acidosis, Headache, Insomnia, Paradoxical bronchospasm, Severe asthma exacerbation
Mechanism of Action
Formoterol relaxes the bronchial smooth muscle by selectively acting on beta2-receptors with minimal effect on heart rate. It has a long-acting effect.
Note
Oxis Turbuhaler 9mcg/Dose Inhaler / Dry Powder manufactured by ASTRAZENECA AB. Its generic name is Formoterol Fumarate. Oxis Turbuhaler is availble in United Arab Emirates.
Farmaco UAE drug index information on Oxis Turbuhaler Inhaler / Dry Powder is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.